Satraplatin or active metabolite kills prostate cancer in vitro
Treatment of prostate cancer cells with satraplatin or its active metabolite resulted in the killing of tumor cells, according to a poster presented at the American Association for Cancer Research's Basic, Translational, and Clinical Advances in Prostate Cancer meeting.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.